Thomas C. Hanff

Thomas C. Hanff, MD, MSCE

Languages spoken: English

Clinical Locations

Saint Alphonsus Regional Medical Center

208-367-2121

  • Dr. Thomas Hanff is an Assistant Professor of Medicine at the University of Utah and the Salt Lake VA Medical Center. Dr. Hanff graduated Summa Cum Laude from the University of California, Los Angeles with a major in Neuroscience and a minor in Public Policy (2008). He received his medical degree and Master of Public Health from the Johns Hopkins University Schools of Medicine and Public Health (2013). He then trained at the University of Pennsylvania where he completed internship and residency in Internal Medicine (2016) and fellowships in Cardiovascular Disease (2019) and Advanced Heart Failure and Transplant Cardiology (2021). He also completed a Master of Science in Clinical Epidemiology while at the University of Pennsylvania (2020). He joined the faculty at the University of Utah, Division of Cardiovascular Medicine in 2021.

    Dr. Hanff specializes in the care of patients with advanced heart failure of all types, both in the hospital and in the outpatient setting. He has extensive expertise in the management of patients who require advanced heart failure therapies such as left ventricular assist devices, heart transplantation, or inotropic therapy. He also specializes in the care of patients with acute decompensated heart failure or cardiogenic shock and in the use of temporary mechanical circulatory support devices as a bridge to recovery or more definitive therapy. He strives to practice at the forefront of evidence-based medicine, with personalized therapeutic plans for every patient matched to their underlying illness and goals of care.

    Dr. Hanff’s research is motivated by two simple questions: 1) Which patients would benefit from various advanced heart failure therapies and 2) When is the optimal time to offer each therapy to a patient based on their individual characteristics? To answer these questions, Dr. Hanff has developed a research program that couples traditional outcomes research with personalized “omics” approaches, using advanced statistical modeling techniques, bioinformatics, and machine learning. He collaborates with several highly regarded researchers throughout the world and works closely with numerous landmark national and international cohorts. His work has been published in top medical journals including JAMA Cardiology, Circulation Heart Failure, Lancet Respiratory Medicine, the Journal of Heart and Lung Transplantation, JACC: Basic to Translational Science, Hypertension, and Stroke.

    Dr. Hanff is board certified in Internal Medicine, Cardiovascular Medicine, and Echocardiography. He is involved with numerous professional societies including the International Society for Heart and Lung Transplantation, the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology, for which he has served on the Clinical Data Standards Task Force.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    National Board of Echocardiography
    National Board of Medical Examiners

  • Dr. Thomas Hanff is an Assistant Professor of Medicine at the University of Utah and the Salt Lake VA Medical Center. Dr. Hanff graduated Summa Cum Laude from the University of California, Los Angeles with a major in Neuroscience and a minor in Public Policy (2008). He received his medical degree and Master of Public Health from the Johns Hopkins University Schools of Medicine and Public Health (2013). He then trained at the University of Pennsylvania where he completed internship and residency in Internal Medicine (2016) and fellowships in Cardiovascular Disease (2019) and Advanced Heart Failure and Transplant Cardiology (2021). He also completed a Master of Science in Clinical Epidemiology while at the University of Pennsylvania (2020). He joined the faculty at the University of Utah, Division of Cardiovascular Medicine in 2021.

    Dr. Hanff specializes in the care of patients with advanced heart failure of all types, both in the hospital and in the outpatient setting. He has extensive expertise in the management of patients who require advanced heart failure therapies such as left ventricular assist devices, heart transplantation, or inotropic therapy. He also specializes in the care of patients with acute decompensated heart failure or cardiogenic shock and in the use of temporary mechanical circulatory support devices as a bridge to recovery or more definitive therapy. He strives to practice at the forefront of evidence-based medicine, with personalized therapeutic plans for every patient matched to their underlying illness and goals of care.

    Dr. Hanff’s research is motivated by two simple questions: 1) Which patients would benefit from various advanced heart failure therapies and 2) When is the optimal time to offer each therapy to a patient based on their individual characteristics? To answer these questions, Dr. Hanff has developed a research program that couples traditional outcomes research with personalized “omics” approaches, using advanced statistical modeling techniques, bioinformatics, and machine learning. He collaborates with several highly regarded researchers throughout the world and works closely with numerous landmark national and international cohorts. His work has been published in top medical journals including JAMA Cardiology, Circulation Heart Failure, Lancet Respiratory Medicine, the Journal of Heart and Lung Transplantation, JACC: Basic to Translational Science, Hypertension, and Stroke.

    Dr. Hanff is board certified in Internal Medicine, Cardiovascular Medicine, and Echocardiography. He is involved with numerous professional societies including the International Society for Heart and Lung Transplantation, the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology, for which he has served on the Clinical Data Standards Task Force.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Cardiovascular Medicine
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Cardiovascular Disease)
    National Board of Echocardiography
    National Board of Medical Examiners

    Education history

    Fellowship Advanced Heart Failure and Transplant Cardiology - University of Pennsylvania Fellow
    Clinical Epidemiology - University of Pennsylvania Department of Biostatistics, Epidemiology, and Informatics M.S.C.E
    Fellowship Cardiology - University of Pennsylvania Fellow
    Medicine - University of Pennsylvania Resident
    Internship Medicine - University of Pennsylvania Intern
    Master of Public Health - Johns Hopkins Bloomberg School of Public Health M.P.H.
    Professional Medical Medicine - Johns Hopkins University School of Medicine M.D.
    Neuroscience - University of California, Los Angeles B.S.

    Selected Publications

    Journal Article

    1. Browne A, Gaines H, Alharethi R, Goodwin M, Selzman CH, Fang JC, Drakos SG, Stehlik J, Hanff TC (2022). Interrupted Time Series Analysis of Donor Heart Use Before and After the 2018 UNOS Heart Allocation Policy Change. J Card Fail, 29(2), 220-224.
    2. Cohen JB, Mitchell GF, Gill D, Burgess S, Rahman M, Hanff TC, Ramachandran VS, Mutalik KM, Townsend RR, Chirinos JA (2022). Arterial Stiffness and Diabetes Risk in Framingham Heart Study and UK Biobank. Circ Res, 131(6), 545-554.
    3. Shore S, Hanff TC, Mazurek JA, Fox A, Tanna MS, Grandin EW, Zhang R, Wald J, Peters C, Acker MA, Atluri P, Rame JE, Goldberg LR, Jessup M, Margulies KB, Birati EY (2022). The Anemia Stress Index-Anemia, Transfusions, and Mortality in Patients with Continuous Flow Ventricular Assist Devices. J Clin Med, 11(15).
    4. Peters CJ, Hanff TC, Genuardi MV, Zhang R, Domenico C, Atluri P, Mazurek JA, Urgo K, Wald J, Tanna MS, Shore S, Acker MA, Goldberg LR, Margulies KB, Birati EY (2022). Safety and Effectiveness of Intravenous Iron Therapy in Patients Supported by Durable Left Ventricular Assist Devices. J Clin Med, 11(13).
    5. Sadeh B, Ugolini S, Pinzon OW, Potapov EV, Selzman CH, Bader F, Zuckermann AO, Gomez-Mesa JE, Shah KS, Alharethi R, Morejon-Barragan P, Hanff T, Goldraich LA, Farrero M, MacDonald PS, Drakos S, Mehra MR, Stehlik J (2022). Medical decisions in organ donors and heart transplant candidates with history of COVID-19 infection: An international practice survey. Clin Transplant, 36(7), e14733.
    6. Zhang RS, Hanff TC, Peters CJ, Evans PT, Marble J, Rame JE, Atluri P, Urgo K, Tanna MS, Mazurek JA, Acker MA, Cevasco M, Birati EY, Wald JW (2022). Left Ventricular Assist Device as a Bridge to Recovery: Single Center Experience of Successful Device Explantation. ASAIO J, 68(6), 822-828.
    7. Edelson JB, Edwards JJ, Katcoff H, Mondal A, Chen F, Reza N, Hanff TC, Griffis H, Mazurek JA, Wald J, Burstein DS, Atluri P, OConnor MJ, Goldberg LR, Zamani P, Groeneveld PW, Rossano JW, Lin KY, Birati EY (2022). Novel Risk Model to Predict Emergency Department Associated Mortality for Patients Supported With a Ventricular Assist Device: The Emergency Department-Ventricular Assist Device Risk Score. J Am Heart Assoc, 11(2), e020942.
    8. Zamani P, Proto EA, Wilson N, Fazelinia H, Ding H, Spruce LA, Davila A Jr, Hanff TC, Mazurek JA, Prenner SB, Desjardins B, Margulies KB, Kelly DP, Arany Z, Doulias PT, Elrod JW, Allen ME, McCormack SE, Schur GM, DAquilla K, Kumar D, Thakuri D, Prabhakaran K, Langham MC, Poole DC, Seeholzer SH, Reddy R, Ischiropoulos H, Chirinos JA (2021). Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. ESC Heart Fail, 8(4), 2698-2712.
    9. Genuardi MV, Moss N, Najjar SS, Houston BA, Shore S, Vorovich E, Atluri P, Molina M, Chambers S, Sharkoski T, Hsich E, Estep JD, Owens AT, Alexander KM, Chaudhry SP, Garcia-Cortes R, Molina E, Rodrigo M, Wald MJ, Margulies KB, Hanff TC, Zimmer R, Kilic A, Mclean R, Vidula H, Dodd K, Blumberg EA, Mazurek JA, Goldberg LR, Alvarez-Garcia J, Mancini D, Teuteberg JJ, Tedford RJ, Birati EY (2021). Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. J Heart Lung Transplant, 40, 926-935.
    10. Khatana SAM, Hanff TC, Nathan AS, Dayoub EJ, Grandin EW, Rame JE, Fanaroff AC, Giri J, Groeneveld PW (2021). Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circ Heart Fail, 14(5), e008277.
    11. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One, 16(4), e0248080.
    12. Birati EY, Najjar SS, Tedford RJ, Houston BA, Shore S, Vorovich E, Atluri P, Urgo K, Molina M, Chambers S, Escobar N, Hsich E, Estep JD, Alexander KM, Teuteberg JJ, Chaudhry SP, Ravichandran A, DeVore AD, Margulies KB, Hanff TC, Zimmer R, Kilic A, Wald JW, Vidula H, Martens J, Blumberg EA, Mazurek JA, Owens AT, Goldberg LR, Alvarez-Garcia J, Mancini DM, Moss N, Genuardi MV (2021). Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circ Heart Fail, 14(4), e007957.
    13. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, Andrade-Villanueva JF, Barbagelata A, Cristodulo-Cortez R, Daz-Cucho OA, Spaak J, Alfonso CE, Valdivia-Vega R, Villavicencio-Carranza M, Ayala-Garca RJ, Castro-Callirgos CA, Gonzlez-Hernndez LA, Bernales-Salas EF, Coacalla-Guerra JC, Salinas-Herrera CD, Nicolosi L, Basconcel M, Byrd JB, Sharkoski T, Bendez-Huasasquiche LE, Chittams J, Edmonston DL, Vasquez CR, Chirinos JA (2021). Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med, 9(3), 275-284.
    14. Edelson JB, Edwards JJ, Katcoff H, Mondal A, Reza N, Hanff TC, Griffis H, Mazurek JA, Wald J, Owens AT, Burstein DS, Atluri P, OConnor MJ, Goldberg LR, Zamani P, Groeneveld PW, Rossano JW, Lin KY, Birati EY (2021). An Increasing Burden of Disease: Emergency Department Visits Among Patients With Ventricular Assist Devices From 2010 to 2017. J Am Heart Assoc, 10(4), e018035.
    15. Hanff TC, Cohen JB, Zhao L, Javaheri A, Zamani P, Prenner SB, Rietzschel E, Jia Y, Walsh A, Maranville J, Wang Z, Adam L, Ramirez-Valle F, Schafer P, Seiffert D, Gordon DA, Cvijic ME, Cappola TP, Chirinos JA (2021). Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci, 6(2), 89-99.
    16. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA (2020). Thrombosis in COVID-19. Am J Hematol, 95(12), 1578-1589.
    17. Shore S, Hanff TC, Mazurek JA, Seigerman M, Zhang R, Grandin EW, Vorovich E, Mather P, Olt C, Howard J, Wald J, Acker MA, Goldberg LR, Atluri P, Margulies KB, Rame JE, Birati EY (2020). The effect of transfusion of blood products on ventricular assist device support outcomes. ESC Heart Fail, 7(6), 3573-3581.
    18. Chirinos JA, Cohen JB, Zhao L, Hanff T, Sweitzer N, Fang J, Corrales-Medina V, Anmar R, Morley M, Zamani P, Bhattacharya P, Brandimarto J, Jia Y, Basso MD, Wang Z, Ebert C, Ramirez-Valle F, Schafer PH, Seiffert D, Gordon DA, Cappola T (2020). Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. Hypertension, 76(5), 1526-1536.
    19. Cohen JB, Hanff TC, Corrales-Medina V, William P, Renna N, Rosado-Santander NR, Rodriguez-Mori JE, Spaak J, Andrade-Villanueva J, Chang TI, Barbagelata A, Alfonso CE, Bernales-Salas E, Coacalla J, Castro-Callirgos CA, Tupayachi-Venero KE, Medina C, Valdivia R, Villavicencio M, Vasquez CR, Harhay MO, Chittams J, Sharkoski T, Byrd JB, Edmonston DL, Sweitzer N, Chirinos JA (2020). Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich), 22(10), 1780-1788.
    20. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM (2020). Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. Clin Infect Dis, 71(15), 870-874.
    21. Cohen JB, Hanff TC, Bress AP, South AM (2020). Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. Curr Hypertens Rep, 22(7), 44.
    22. Hanff TC, Harhay MO, Kimmel SE, Molina M, Mazurek JA, Goldberg LR, Birati EY (2020). Trends in Mechanical Support Use as a Bridge to Adult Heart Transplant Under New Allocation Rules. JAMA Cardiol, 5(6), 728-729.
    23. Hanff TC, Kaye DM, Hayward CS, Post MC, Malek F, Hasenfu G, Gustafsson F, Burkhoff D, Shah SJ, Litwin SE, Kahwash R, Hummel SL, Borlaug BA, Solomon SD, Lam CSP, Komtebedde J, Silvestry FE, REDUCE LAP-HF study investigators and research staff (2019). Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). Am J Cardiol, 124(12), 1912-1917.
    24. Birati EY, Hanff TC, Maldonado D, Grandin EW, Kennel PJ, Mazurek JA, Vorovich E, Seigerman M, Howard JLL, Acker MA, Naka Y, Wald J, Goldberg LR, Jessup M, Atluri P, Margulies KB, Schulze PC, Rame JE (2018). Predicting Long Term Outcome in Patients Treated With Continuous Flow Left Ventricular Assist Device: The Penn-Columbia Risk Score. J Am Heart Assoc, 7(6).
    25. Gopal DJ, Hanff TC, Mazurek JA, Grandin WE, Howard J, Forde-McLean R, Wald J, King K, Acker MA, Goldberg LR, Jessup M, Atluri P, Margulies KB, Rame EJ, Birati EY (2017). Prognostic Implications of Changes in Albumin Following Left Ventricular Assist Device Implantation in Patients With Severe Heart Failure. Am J Cardiol, 120(11), 2003-2007.
    26. Birati EY, Mathelier H, Molina M, Hanff TC, Mazurek JA, Atluri P, Acker MA, Rame JE, Margulies KB, Goldberg LR, Jessup M (2016). Comparison of Causes of Death After Heart Transplantation in Patients With Left Ventricular Ejection Fractions ≤35% Versus >35. Am J Cardiol, 117(8), 1322-6.
    27. Golbus JR, Manly DA, Wonneberger KA, Hanff TC, Murphy KM, Wang DS, McKee SG, Bellini L (2015). Implementation of a Novel, Resident-Led, Nocturnal Curriculum. J Grad Med Educ, 7(3), 417-21.
    28. Minor TR, Hanff TC (2015). Adenosine signaling in reserpine-induced depression in rats. Behav Brain Res, 286, 184-91.
    29. Hanff TC, Sharrett AR, Mosley TH, Shibata D, Knopman DS, Klein R, Klein BE, Gottesman RF (2014). Retinal microvascular abnormalities predict progression of brain microvascular disease: an atherosclerosis risk in communities magnetic resonance imaging study. Stroke, 45(4), 1012-7.
    30. Gill RS, Hambridge HL, Schneider EB, Hanff T, Tamargo RJ, Nyquist P (2012). Falling temperature and colder weather are associated with an increased risk of aneurysmal subarachnoid hemorrhage. World Neurosurg, 79(1), 136-42.
    31. Hanff TC, Furst SJ, Minor TR (2010). Biochemical and anatomical substrates of depression and sickness behavior. Isr J Psychiatry Relat Sci, 47(1), 64-71.

    Review

    1. Tehrani BN, Drakos SG, Billia F, Batchelor WB, Luk A, Stelling K, Tonna J, Rosner C, Hanff T, Rao V, Brozzi NA, Baran DA (2022). The Multicenter Collaborative to Enhance Biologic Understanding, Quality, and Outcomes in Cardiogenic Shock (VANQUISH Shock): Rationale and Design. [Review]. Can J Cardiol, 38(8), 1286-1295.
    2. Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, Muser D, Ferrari VA, Nazarian S, Santangeli P, Deo R, Cooper LT Jr, Mohiddin SA, Chahal CAA (2022). The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. [Review]. JACC Basic Transl Sci, 7(3), 294-308.

    Editorial

    1. Hanff TC, Kemeyou L (2021). Impaired Forced Expiratory Volume Across the Heart Failure Spectrum. Chest, 161(1), 11-12.
    2. Siripanthong B, Hanff TC, Levin MG, Vidula MK, Khanji MY, Nazarian S, Chahal CAA (2020). Coronavirus disease 2019 is delaying the diagnosis and management of chest pain, acute coronary syndromes, myocarditis and heart failure. Future Cardiol, 17(1), 3-6.
    3. Hanff TC, Birati EY (2019). Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support. Curr Heart Fail Rep, 16(5), 168-179.

    Letter

    1. Edwards JJ, Edelson JB, Katcoff H, Mondal A, Lefkowitz D, Reza N, Hanff TC, Griffis H, Mazurek JA, Wald J, Owens AT, Wittlieb-Weber CA, Burstein DS, Atluri P, OConnor MJ, Goldberg LR, Zamani P, Groeneveld PW, Rossano JW, Lin KY, Birati EY (2021). Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients. [Letter to the editor]. Am Heart J, 240, 11-15.
    2. Hanff TC, Goldberg LR, Birati EY (2020). Venoarterial Extracorporeal Membrane Oxygenation to Heart Transplant-An Inflamed Bridge?-Reply. [Letter to the editor]. JAMA Cardiol, 6(3), 362-363.
    3. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM (2020). Reply to Tedeschi et al. [Letter to the editor]. Clin Infect Dis, 71(15), 901.
    4. Hanff TC, Harhay MO, Kimmel SE, Birati EY, Acker MA (2020). Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States. [Letter to the editor]. J Heart Lung Transplant, 39(7), 725-726.
    5. Cohen JB, Hanff TC, South AM, Sparks MA, Hiremath S, Bress AP, Byrd JB, Chirinos JA (2020). Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". [Letter to the editor]. Circ Res, 126(12), e140-e141.